Market Exclusive

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Regulation FD Disclosure

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Regulation FD Disclosure
Item 7.01

PROTEOSTASIS THERAPEUTICS, INC. Exhibit
EX-99.1 2 d692089dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p<0.05) in Subjects with Two F508del Mutations (F/F) Not Predisposed to Rapid Pulmonary Decline All Combinations Studied Were Well-Tolerated,…
To view the full exhibit click here

About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Exit mobile version